Vivos Therapeutics, Inc. Debt Conversion, Converted Instrument, Amount
Vivos Therapeutics, Inc. (VVOS) reported Debt Conversion, Converted Instrument, Amount of $2.64 million for the 3-month period ending 2020-03-31, per its 10-Q filed 2021-05-17.
Discontinued › Cash Flow › Financing Activities
us-gaap:DebtConversionConvertedInstrumentAmount1 · last filed 2021-05-17
- Vivos Therapeutics, Inc. debt conversion, converted instrument, amount for the quarter ending 2020-03-31 was $2.64M.
| Period end | Debt Conversion, Converted Instrument, Amount 3 month |
|---|---|
| 2020-03-31 | $2.64M 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beyond Air, Inc. (XAIR) | United States | $0.003B | -0.01 |
| NEXGEL, INC. (NXGL) | United States | $0.002B | |
| INVO Fertility, Inc. (IVF) | United States | $0.002B | -0.71 |
| Catheter Precision, Inc. (VTAK) | United States | $0.002B | -0.23 |
| Tenon Medical, Inc. (TNON) | United States | $0.002B | |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| Profusa, Inc. (PFSA) | United States | $0.002B | |
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Bluejay Diagnostics, Inc. (BJDX) | United States | $0.004B |